CHD4

Across TCGA pan-cancer cohorts, CHD4 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CHD4 data layer compared with 26 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher CHD4 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated CHD4 expression acts as an unfavorable survival marker, although some lineages such as GBM and LSCC show a favorable association.

CCRCC, GBM, and LSCC are the cancer types where CHD4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	All	0.905	0.983	.027	4	view →
GBM	OS	Median	All	0.631	0.454	.022	4	view →
LSCC	OS	Median	All	0.887	0.750	.041	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

CHD4–CCRCC (OS)

Open the CCRCC breakdown →